恩瑞格售价多少一盒？

It was approved by the European Commission in December 2012 for the treatment of chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy.

Enrig is a commonly used drug to relieve iron accumulation. So, how much does a box of Enrig cost?

Enrig price:

The price of Desirox is relatively high after it is launched in China, with a box costing about $2,000. For an ordinary person weighing 60kg, the cost of taking Desirox for a month is more than about $24,000. It can be seen that it is difficult for ordinary families to accept this price and cannot afford it!  

Fortunately, there are also foreign versions for everyone to choose from. Novartis of Switzerland imported Desirox to India. The specification is 400mg*30 tablets/box, and the price is about $700.  

The specification of Desirox produced by Indian pharmaceutical factory is 500*30 tablets/box, and the price is about 500$. Due to the fluctuation of exchange rate, the price will be different. Please consult the medical companion for the specific price!

Adverse reactions of Enrig:

In phase III clinical studies, it was observed that certain acute adverse reactions could occur with high-dose use of Enriga, such as gastrointestinal symptoms in 15% and rash in 11%, but patients who discontinued treatment due to these symptoms were rare.

In 2008, the U.S. FDA received a report of a patient with encephalopathy who developed liver failure after taking Enriga for 5 days. The report revealed that the patient had a history of alcohol abuse and mild liver function abnormalities.

In addition, the patient had no indications for medication, and his serum ferritin level was 10% of the medication indications recommended in the drug instructions. The patient's liver function returned to normal after stopping the drug.

Bauters from Ghent University Hospital in Belgium reported a case of gastric ulcer in a child with thalassemia major after treatment. According to the adverse reactions of Enriga reported in recent years, this case is the first, so it requires sufficient attention.